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Abstract
Gene transfer is a widely developed technique for studying and treating genetic diseases. However, the development of
therapeutic strategies is challenging, due to the cellular and functional complexity of the central nervous system (CNS), its
large size and restricted access. We explored two parameters for improving gene transfer efficacy and capacity for the
selective targeting of subpopulations of cells with lentiviral vectors (LVs). We first developed a second-generation LV
specifically targeting astrocytes for the efficient expression or silencing of genes of interest, and to better study the
importance of cell subpopulations in neurological disorders. We then made use of the retrograde transport properties of a
chimeric envelope to target brain circuits affected in CNS diseases and achieve a broad distribution. The combination of
retrograde transport and specific tropism displayed by this LV provides opportunities for delivering therapeutic genes to
specific cell populations and ensuring high levels of transduction in interconnected brain areas following local
administration. This new LV and delivery strategy should be of greater therapeutic benefit and opens up new possibilities for
the preclinical development of gene therapy for neurodegenerative diseases.
Introduction
The central nervous system (CNS) is a highly complex
organ, and our knowledge of its physiological and patho-
physiological functions and mechanisms remains incomplete
[1]. A genetic origin has been found for some CNS diseases,
including Huntington’s disease (HD), familial forms of
amyotrophic lateral sclerosis, Parkinson’s disease (PD), and
Alzheimer’s disease [1]. The use of gene replacement or
gene silencing strategies to target the corresponding disease
genes is a promising therapeutic approach for these condi-
tions [2]. Viral vectors are widely used to ensure the effi-
cient, sustained and safe delivery of the genes of interest to
the CNS. Zolgensma® (AAV-smn) has recently been
approved for the treatment of infants with spinal muscular
atrophy [3]. Gene replacement and RNA interference stra-
tegies are currently being developed for adrenoleukodystro-
phy [4], lysosomal storage disorders [5], HD [6], and PD [7].
Neuronal cells are the principal cells targeted and
transduced following the intraparenchymal administration
of viral vectors. However, both neuronal and non-neuronal
cells contribute to neurodegenerative disorders [8]. Thus,
viral vectors targeting neurons alone may be insufficient for
the effective treatment of brain disorders. Astrocyte-specific
viral vectors have been developed for studies of the con-
tribution of astrocytes to such conditions and the mechan-
isms involved [9]. These vectors were generated by altering
the ability of vectors to bind to and enter host cells and by
integrating transcriptional and post-transcriptional reg-
ulatory elements into the vector. Another challenge in the
development of CNS treatments is the degeneration of
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specific regions of the brain at early stages, and of much
larger areas of the brain at later stages observed in most
neurodegenerative disorders. The affected areas form
interconnected neural circuits and constitute large functional
networks [10]. For instance, HD is characterized by a spe-
cific vulnerability of the medium-spiny GABAergic neurons
of the striatum, although other structures that receive or
send projections to/from the striatum also degenerate during
disease progression [11].
Transduction of the specific cell populations affected in
these brain circuits should be considered, to maximize
therapeutic benefits. The most potent viral vectors for CNS
applications are adeno-associated viral vectors (AAV) and
lentiviral vectors (LV) [12]. Diverse AAV serotypes and
variants with high retrograde and/or anterograde transport
properties have been described in the last few years. For
example, the AAV2-retro variant displays levels of retro-
grade transport two orders of magnitude greater than those
of commonly used AAV serotypes [13]. For LV, the most
widely used envelope is the vesicular stomatitis virus
G-glycoprotein (VSV-G). However, VSV-G-pseudotyped
LV (LV-VSVG) can only transduce cells at the site of
injection. Researchers have made use of neurotropic viru-
ses, which display natural retrograde spread during their life
cycle to demonstrate that LV pseudotyping with the rabies
virus G-glycoprotein (RV-G) leads to retrograde transport
and expression in distal neurons [14]. Several groups have
developed chimeric rabies/VSV-G envelopes for the pseu-
dotyping and transduction of neurons in projecting areas
[15]. Various strains of rabies virus and configurations
of the chimera were used in these studies [16]. Hirano
and coworkers developed two RV-G/VSV-G fusion
glycoproteins: FuG-B (from the Pasteur virus strain),
with high levels of retrograde transport HiRet [17–19], and
FuG-E, displaying neuron-specific retrograde gene transfer
(NeuRet) [20].
We explored the possibility of using LVs pseudotyped
with the chimeric glycoproteins FuG/B2 to target neurons
and astrocytes. We also used the neuronal connectome [21]
and the retrograde transport properties of LV-FuG/B2
following injection into a highly interconnected area of the
brain to increase transduction efficiency. We found that
this delivery strategy significantly enhanced gene transfer,
resulting in a widespread distribution of the vector in large
areas of the brain following intrastriatal injection.
Materials and methods
Plasmids and lentiviral vector production
The GfaABC1D promoter was kindly provided by
Dr. Michael Brenner through the support of NIH grant
NS39055 [22, 23]. The GfaABC1D promoter was EcoRI-
digested from the pGFA-ABC1D plasmid [22] and cloned
into the gateway entry vector EcoRI-digested pENTR4
(Roche Diagnostics, Switzerland). The (B)3 enhancer
(431 bp) (B sequence Genbank NG_008401: position 3436-
3559) was obtained from Bsu36i/SmaI-digested pUC-GFa2
(B)3-nls-LacZ plasmid and ligated into Bsu36i/SmaI-
digested pENTR4-GFaABC1D. The GFaABC1D(B)3 pro-
moter, hereafter called G1B3, was then digested with
BamHI, treated with Klenow to generate blunt ends (Sigma
Aldrich, Switzerland), and cloned into Spe/blunt-digested
SIN-cPPT-gateway-WPRE-miR124T transfer vector [24].
We used LV expressing the DsRednuc, mCherry, or
GFP fluorescent reporter genes under the control of the
mouse PGK1 or GfaABC1D(B)3 promoters, the wood-
chuck post-transcriptional regulatory element (WPRE) and
the miR124 targeting sequence (miR124T). The following




mCherry-WPRE [24–26]. These LVs were pseudotyped
with the VSV-G and FuG/B2 envelopes [18] and produced
in HEK-293T cells with a four-plasmid system, as pre-
viously described [27].
The Vivapure LentiSELECT 500 kit was used for
the small-scale purification of lentiviral particles, as pre-
viously described [28] (Thermo Fisher Scientific, Reinach,
Switzerland). The Sartobind® ion exchange membrane
adsorber technology used in LentiSELECT efficiently and
rapidly captures and recovers large viral particles (3000 nm
pores). The particle content of viral batches was determined
by p24 antigen ELISA (RETROtek, Gentaur, Kampenhout,
Belgium). The stocks were stored in 1% BSA in PBS at
−80 °C until use.
Primary cultures and transduction of cortical
astrocytes
For astrocyte cultures, P1 C57BL/6 mouse pups (Charles
River, Ecully, France) were killed by decapitation. Brain
cortical tissues were cut into small pieces and mechanically
dissociated by repeated aspiration in a fire-polished Pasteur
pipette. The dissociated astrocytes were centrifuged at
500 × g for 2 min, and the pellet was resuspended in 1 ml of
10% fetal bovine serum (FBS) in DMEM. The cells col-
lected from three pups were used to seed a single T75 flask
containing DMEM (Sigma-Aldrich Chemie GmbH, Buchs,
Switzerland), 10% FBS (Life Technologies, Zug, Switzer-
land), 1% antibiotic-antimycotic solution (Sigma-Aldrich
Chemie GmbH, Buchs, Switzerland) and 3.7 g/L sodium
bicarbonate, pH 7.2. The medium was replaced with fresh
culture medium three days after seeding, and then every
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5–7 days thereafter. At the first medium change, the flasks
were strongly shaken three times to remove microglia, and
washed with PBS to remove dead cells. After 2 weeks in
culture, the astrocytes were released by trypsin treatment
and used to seed a T125 flask at a density of 100,000 cells/
ml. Once 90% confluence was reached, the astrocytes
were replated in a 24-well plate coated with 15 mg/L
poly-L-ornithine (Sigma-Aldrich Chemie GmbH, Buchs,
Switzerland), at a density of 100,000 cells/ml. Astrocyte
cultures were infected on day 8 with 100 ng SIN-cPPT-
G1B3-GFP-WHV-miR124T or 100 ng SIN-GfaABC1D-
GFP-WHV-miR124T, and maintained in culture for
1 week. As a negative control, we used noninfected cells.
Immunofluorescence staining of primary cultures of
cortical astrocytes
Eight days post-infection, the medium was removed and the
astrocytes were washed twice with cold PBS and incubated
for 20 min at 4 °C with 4% PFA. The coverslips were
washed with PBS to remove the residual PFA and blocked
by incubation for 1 h in 1x PBS supplemented with 10%
normal goat serum (NGS, Interchim, Montluçon, France)
and 0.03% Triton X-100 (Fluka, Sigma-Aldrich, Buchs,
Switzerland). A rabbit polyclonal anti-GFAP primary anti-
body (RRID: AB_10013382, 1/800, Dako Schweiz AG,
Basel, Switzerland) was diluted in 1x PBS −10% NGS
−0.03% Triton X-100 and incubated overnight with the
cells at 4 °C. The cells were then washed three times, for
five minutes each, with 1x PBS, and incubated for 1 h at
room temperature (RT) with a goat anti-rabbit IgG
AlexaFluor-594 secondary antibody (1/1000, Invitrogen,
Life Technologies, Zug, Switzerland) diluted in 1x PBS
−10% NGS –0.03% Triton X-100. Cells were then washed
3 times, for 5 min each, in 1x PBS, and mounted in Vec-
tashield HardSet mounting medium (Vector Labs, H-1500).
Images were acquired with a x10 objective on a Zeiss
AxioVision epifluorescence microscope (Zeiss, Carl Zeiss
Microscopy GmbH, Göttingen, Germany). Quantification of
DAPI/GFAP demonstrated that the culture contains >85%
astrocytes.
Measurement of mean fluorescence in primary
cortical astrocyte cultures
The coverslip with the fixed cortical astrocytic primary
cultures were used to measure the mean fluorescence
intensity per cell. Images were acquired using the 10x
objective of the Zeiss Axio Imager Z1 upright microscope
Zeiss, (Car Zeiss Microscopy GmbH, Göttingen, Germany)
setting the same exposure time for all the acquisition ses-
sions (500 ms). The GFP-positive cells were manually
delimited and the mean gray level of each one was
automatically calculated using the ImageJ software. Graphs
representing the distribution of MFI/cell were obtained with
GraphPad software (GraphPad Prism version 8.00 for
Windows, GraphPad Software, La Jolla California USA,
www.graphpad.com). Data are expressed as mean ± SD.
G1B3-GFP: n= 7; GfaABC1D-GFP: n= 3.
Culture and transduction of HEK-293T cells
HEK-293T cells (CRL11268, ATCC/LGC standards,
Wesel, Germany) were cultured in DMEM supplemented
with 10% FBS, 100 U/ml penicillin, and 100 µg/ml strep-
tomycin, at 37 °C under an atmosphere of 5% CO2 in air.
On the day before infection, HEK-293T cells were plated, at
a density of 140,000 cells per well, in 12-well plates
(Corning, Life Technologies, Zug, Switzerland) and incu-
bated for one day. They were then infected with various
amounts of SIN-PGK-GFP-WPRE (5, 10, 25, 50, 100 ng
p24). Three days later, GFP expression was assessed in
wells containing a coverslip coated with 5 µg/ml poly-D-
lysine (Corning, Life Technologies, Zug, Switzerland) in
HBSS (Thermo Fisher Scientific, Reinach, Switzerland).
The samples were fixed with 4% paraformaldehyde (PAF;
Lucerna Chem, Lucerne, Switzerland) in Vectashield with
DAPI (Reactolab, Servion, Switzerland).
DNA and RNA were extracted from the other wells with
TRIzol® (Thermo Fisher, St-Aubin, France). DNA and
RNA concentrations were determined with a Nanodrop
spectrophotometer (Thermo Fisher Scientific, Reinach,
Switzerland). The entire procedure was performed in
DNAse-free conditions, in a clean area free of plasmids and
PCR products, to prevent sample contamination.
Vector copy number (VCN) and RT-qPCR in HEK-
293T cells
VCN was determined as previously described [29]. We used
qLV-HIVgag primers (forward: TCTCGACGCAGGAC
TCG; reverse: TACTGACGCTCTCGCACC; probe:
Yakima-Yellow-ATCTCTCTCCTTCTAGCCTCZNA4-
BHQ1) for the test gene and the housekeeping gene
encoding poly (rC)-binding protein 2 (qPCBP2; forward:
TTGTGTCTCCAGTCTGCTTG; reverse: AGGTGGTGGT
GGTGGTA; probe: FAMCCCTCTCCTGGCTCTAAATG
TTGTGT- BHQ1) and created a standard curve (16 pg-2
ng) for SIN-PGK-GFP-WPRE equivalent to a VCN of
0.16–20 in 100 ng gDNA, adjusting the amount of plasmid
for the size of the human genome (3.1 Gb per haploid
genome) [29]. We used 100 ng of gDNA from HEK-293T
cells for qPCR, in duplicate, in 20 µl reaction mixtures. We
used the KAPA SYBR FAST qPCR kit (Axon Laboratories,
Mont-sur-Lausanne, Switzerland) and 200 nM of each pri-
mer, with a standard PCR program of 5 min at 95 °C
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followed by 40 cycles of 3 s at 95 °C, and 20 s at 60 °C
(RotorGene Q, Qiagen, Hombrechtikon, Switzerland). For
each sample, we analyzed biological duplicates and tech-
nical triplicates. The VCN standard curves were generated
and LV insertion sites in samples were quantified by the the
ΔΔCT method, with PCBP2 as the internal calibrator gene.
RT-qPCR
TRIzol-extracted RNA samples from HEK-293T cells were
treated with RQ1 RNase-free DNase (Promega, Dübendorf,
Switzerland) to remove any trace of genomic DNA. We
then generated cDNA from the RNA with Superscript II
(Thermo Fisher, Reinach, Switzerland), according to the
manufacturer’s guidelines, and diluted it to a final con-
centration of 1 ng/µL. We performed real-time quantitative
PCR on the cDNA with the Kapa Sybr Fast qPCRMaster
mix (Axon Laboratories, Mont-sur-Lausanne, Switzerland),
according to the manufacturer’s protocol, with Rotor Gene
(Qiagen, Basel, Switzerland) and the following cycle
parameters: reaction volume of 20 µl containing 200 nM of
both forward and reverse primers recognizing a WPRE
sequence (WPRE-Fwd: TGTGGATACGCTGCTTTAATG;
WPRE-Rev: CATAAAGAGACAGCAACCAGGA), in a
Realplex thermal cycler (Eppendorf, Montesson, France).
The values obtained for the GFP mRNA were normalized
against the β-actin (ACT-1F: TGAAGGTGACAGCA
GTCGGTTG, ACT-2R: GGCTTTTAGGATGGCAAGG
GAC) reference gene. Technical duplicates were analyzed.
Mean fluorescence intensity measurement in HEK-
293T cells
The coverslips with the fixed HEK-293T cells were used for
measurements of the mean fluorescence intensity per cell.
Images were obtained with a digital camera (3CCD Hitachi
HV-F202SCL) on a slide scanner microscope (10x objec-
tive, Zeiss Axioscan Z1). Integrated optical density was
measured with Zen 2 image analysis software (blue edition).
GFP labeling was quantified by measuring the density of
GFP immunoreactivity on 10 regions of interest (300,000
µm2). The nonspecific optical density of staining was sub-
tracted from the optical density to calculate an optical
density corresponding specifically to GFP.
Animals
The animals were housed in a controlled-temperature
room with a 12 h day/12 h night cycle. Food and water
were available ad libitum. Animals were transferred to our
animal facility 10 days before surgery to allow them to
adapt to the new environment. All experiments were
carried out in accordance with the European Community
directive (86/609/EEC) for the care and use of laboratory
animals and Swiss animal welfare laws, under authoriza-
tion nos. VD 2888, 3073, and 3270 from the Service de la
Consommation et des Affaires Vétérinaires du Canton de
Vaud, Switzerland.
Transgenic mice carrying a bacterial artificial chro-
mosome encoding the enhanced green fluorescent protein
(EGFP) under the control of the D2 dopamine receptor
promoter (Drd2-EGFP) were generated by the GENSAT
(Gene Expression Nervous System Atlas) project [30].
The GLT1-EGFP transgenic mice expressing GFP in
astrocytes were kindly provided by Prof. Jeffrey D.
Rothstein [31].
In vivo experimental design and animals
Concentrated viral stocks were thawed on ice and resus-
pended by repeated pipetting. The mice were anesthetized
with 75 mg/kg ketamine/10mg/kg xylazine, administered
intraperitoneally. The SIN-G1B3-DsRednuc-WPRE viral
vector (n= 3; 200 ng p24 antigen; 2 µl) was injected stereo-
taxically into the striatum of nine-week-old GLT1-EGFP
mice. We injected pCCL-cPPT-H1-shGFP (n= 5 per group;
300 ng p24 antigen; 2 µl) into GLT1-EGFP mice and Drd2-
EGFP mice. The SIN-cPPT-PGK-cherry-WPRE (150 ng p24
antigen/site) and SIN-cPPT-PGK-GFP-WPRE (150 ng p24
antigen/site) viral vectors pseudotyped with the FuG/B2
envelope were co-injected into the striatum (bilaterally) of
C57Bl6 mice (n= 4). Finally, the purified batch of SIN-PGK-
GFP-WPRE (2 × 300 ng p24 antigen; 5 µl) pseudotyped with
the FuG/B2 envelope was injected unilaterally into the stria-
tum of C57Bl6 mice (n= 4).
In all cases, injections were performed with a 34-gauge
blunt-tip needle linked to a Hamilton syringe (Coopers
Needle Works, Birmingham, England) by a polyethylene
catheter, at the following stereotaxic (Kopf model 953,
Phymep, Paris, France) coordinates: 0.5 mm rostral to
bregma, 2 mm lateral to midline, and 3.5 mm from the skull
surface. The final experiment was performed with a uni-
lateral injection into the striatum at the following coordi-
nates: site 1: +1.2 mm rostral to bregma, +2 mm lateral
to midline, and −3.2 mm from the skull surface, site 2:
−0.26 mm rostral to bregma, +2.8 mm lateral to midline,
and −3.2 mm from the skull surface, tooth bar: 1.45.
The various LVs were injected at a rate of 0.2 µl/min or
0.5 µl/min for the final experiment, with an automatic
injector (Harvard Apparatus, Les Ulis, France), and the
needle was left in place for an additional 5 minutes.
The skin was closed with 6-0 Prolene sutures (B-Braun,
Sempach, Switzerland). In all cases, mice were sacrificed
2–3 weeks post injection. No randomization or blinding was
used to allocate the animals to experimental groups and
processed them. The exclusion criteria were technical
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failure during the surgical procedure or post-mortem pro-
cessing of the samples.
Tropism of the VSVG-G1B3 vector
We assessed the astrocytic tropism of VSVG-G1B3,
by acquiring images with a Zeiss LSM 880 Airyscan
inverted confocal microscope (Carl Zeiss Microscopy
CmBH, Göttingen, Germany). The same settings were
maintained throughout the entire experiment (3 animals, 18
hemispheres, one image per hemisphere): 20X enlargement
for z-stack imaging (number of stack) of the striatum. The
infected astrocytes (DsRed2Nuc+, DAPI+, and GFP+ cells)
and non-astrocytic cells (DsRed2Nuc+ and DAPI+ cells,
and GFP- cells) were quantified with Imaris Software. The
cells on the images were counted (DAPI > 300, GLT1
between 1919 and 3938, DsRedNuc > 1090). Tropism for
astrocytes was then calculated by dividing the number of
astrocytes infected with the viral vector (DsRedNuc+ and
GLT1+ cells) by the total number of cells infected with the
viral vector (DsRedNuc+ cells). This quantification was
performed for all samples (n= 18 hemispheres) and is
expressed as the mean ± SD number of infected astrocytes.
Quantitative analysis of mCherry/GFP coexpression
For quantitative analyses following the coinjection of
mcherry and GFP viruses, images were acquired with a x20
objective on a Zeiss LSM 880 AiryScan inverted confocal
microscope (Carl Zeiss Microscopy GmbH, Göttingen,
Germany). For the cortex, images of 807 µm by 807 µm
were acquired with a z-stack of 20 µm. For the striatum,
images of 807 µm by 1.58 mm were acquired with a z-stack
of 20 µm. Acquisition parameters were kept constant for
images obtained within the cortex and within the striatum.
Images were then converted from.czi to.ims files and
imported into IMARIS software 9.3 (Bitplan, RRID:
SCR_007370). We acquired two or three images per ani-
mal. The total number of transduced cells and the numbers
of GFP+ and mCherry+ cells were counted manually.
Mean fluorescence intensity (MFI) per cell
We used the 20x objective of the Zeiss AxioImager Z1
upright microscope (Carl Zeiss Microscopy GmbH, Göt-
tingen, Germany) to acquire images of the GFP-positive
striatal and cortical mouse brain sections, to cover the entire
area and prevent overlap between images. We prevented
saturation and maximized the intensity of GFP fluorescence,
by adjusting the exposure time for acquisition for each of
the two zones while keeping all other parameters the same
(striatum exposure time: 45 ms; cortex exposure time:
600 ms). For each acquisition session, saturation was pre-
vented with a pixel fluorescence intensity histogram. The
GFP-positive cells were manually delimited and the mean
gray level of each cell was automatically calculated with
ImageJ software. For a semi-quantitative comparison
between the striatum and the cortex, the fluorescence levels
for each area were normalized to the same time exposure
(300 ms). Graphs representing the distribution of MFI/cell
were obtained with GraphPad software (GraphPad Prism
version 8.00 for Windows, GraphPad Software, La Jolla
California USA, www.graphpad.com). Data are expressed
as mean ± SD.
In vivo VCN quantification
The unfixed perfused brains were extracted and positioned
in a cold matrix (separated by 1 mm; Phymep, Paris,
France). The brains were then cut into 1 mm sections,
which were placed on an ice-cold glass plane (cooled by
being placed over dry ice, with ethanol added if it became
too cold). For each mouse (n= 3; 6 hemispheres), sec-
tions corresponding to the injection sites were selected.
We did not use staining, and we therefore selected three
sections per mouse. A hole-punch sample was then
obtained for the left hemisphere (non-injected) and the
right hemisphere (injected) of each. These samples were
then transferred out of the biosafety level 2 facility, on ice.
We added 400 μl TRIzol® (Life Technologies, Zug,
Switzerland) to each tube and the tissue was homogenized
with a pellet mixer (VWR, Dietikon, Switzerland). The
tubes were then frozen at −80 °C until use. RNA and
DNA were extracted according to the kit manufacturer’s
protocol. RNA was stored at −80 °C and DNA was
resuspended by incubation overnight in water at RT and
was then stored at 4 °C. VCN was measured as described
for the in vitro analysis of HEK-293T cells.
Histological processing
Two to three weeks after LV injection, the animals were
killed by an overdose of sodium pentobarbital and trans-
cardially perfused with PBS followed by 4% paraformalde-
hyde (PAF) (Fluka, Sigma, Buchs, Switzerland). Brains
were removed and post-fixed by incubation in 4% PAF for
24 h and were then cryoprotected by incubation in 20%
sucrose (Sigma-Aldrich, Buchs, Switzerland) in 0.1M PBS
for 6 h, before storage in 30% sucrose for 24 h. A cryostat
(CM1850, Leica Biosystems, Muttenz, Switzerland) with a
freezing stage at −20 °C (SM2400; Leica Microsystems AG,
Glattbrugg, Switzerland) was used to cut 25 µm-thick cor-
onal brain sections. Sections from the entire striatum were
collected and stored in antifreeze solution (0.2M sodium
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phosphate buffer, glycerol 25%, ethylene glycol 30%) in
96-well plates at −20 °C.
Striatal sections from the mice that had received
injections were processed for immunohistochemistry
for DsRednuc (tdTomato Polyclonal Ab; Sicgen:
RRID: AB_2722750). The striatal sections (25 µm) were
rinsed at RT in TBS (10 mM Tris pH 7.6, 0.9% NaCl)
(3 × 10 min) and blocked by incubation for 1 h in TBST
supplemented with 2.5% normal donkey serum. Sections
were incubated overnight at 4 °C in a solution containing
the primary antibody at a dilution of 1/250. They were
washed three times with TBS (10 mM Tris pH 7.6, 0.9%
NaCl), for 10 min each, and were then incubated with the
Alexa Fluor® 568-conjugated donkey anti-goat secondary
antibody diluted 1/1000 (IgG (H+L), highly cross-
adsorbed: A-11057; Life Technologies, Zug, Switzerland)
for 1 h at RT. Finally, the brain sections were washed
three times, for 10 minutes each, in TBS and mounted on
slides in Vectashield with DAPI (Reactolab, Servion,
Switzerland).
CLARITY sample preparation and lightsheet imaging
Mice were perfused with 4% PFA and tissues were post-
fixed by overnight incubation in 4% PFA. Brains
were clarified according to the CLARITY protocol [32],
with X-CLARITY, a commercial system for electro-
phoretic tissue clearing (www.logosbio.com). Brains were
immersed in a refractive index matching solution (RIMS)
containing Histodenz (Sigma Aldrich, Buchs, Switzer-
land) for at least 24 h before imaging. After clearing,
brains were glued to a holder and immersed in a 10 × 20 ×
45 mm quartz cuvette filled with RIMS. The cuvette was
then placed in a chamber filled with oil with n= 1.45
(Cargille). It was then observed with a dual-sided exci-
tation path, a fiber-coupled multiline laser combiner (405,
488, 561, and 647 nm, Toptica MLE), and a detection path
comprising a 42 Olympus MVX-10 zoom macroscope
with a 1× objective (Olympus MVPLAPO 1×), a filter
wheel (Ludl 96A350), and a scientific CMOS (sCMOS)
camera (Hamamatsu Orca Flash 4.0 V3). The excitation
paths also included galvo scanners for light-sheet gen-
eration and the reduction of shadow artifacts due to light-
sheet absorption. The beam waist was also scanned with
electrically tunable lenses (Optotune EL-16-40-5D-TC-L)
synchronized with the rolling shutter of the sCMOS
camera. This axially scanned light-sheet mode (ASLM)
resulted in a uniform axial resolution across the field-of-
view of 5 μm. Images were acquired with custom-written
Python software. Z-stacks were acquired at a spacing of
5 or 3 μm with a zoom set to a magnification of ×0.8 or
×2, resulting in an in-plane pixel size of 8.23 μm or
3.26 μm, respectively (2048 × 2048 pixels). The excitation
wavelength for GFP was 488 nm and a 530/40 nm emis-
sion bandpass filter (BrightLine HC, AHF) was used.
A complete description of the mesoSPIM microscope was
provided in a previous article [33].
Results
Targeting astrocytes with the VSV-G envelope and
an astrocytic promoter
We and other groups have shown that LVs pseudotyped
with the VSV-G envelope and expressing a GFP reporter
gene under the control of the PGK promoter have a strong
neuronal tropism in rodents [25, 34]. This tropism can be
modified toward astrocytic cells through the use of combi-
nations of a heterologous Mokola envelope, an miRNA
detargeting strategy [22, 35], and astrocytic promoters
[22, 36]. The presence of four copies of the neuron-specific
miRNA-124 target sequence (miR124T) in a MOKOLA-
pseudotyped LV (MOK/LV) suppresses transgene expres-
sion in neurons, but efficiently preserves expression in
astrocytes [24]. Similarly, strong astrocytic expression of
the transgene was obtained by combining the human glial
fibrillary acidic protein (GfaABC1D) [22] or rat glutamine
synthetase (GS) promoter with the miR124T sequence [36].
However, these promoters are associated with weak
transgene expression in vivo and their activity is barely
detectable in primary cultures. Here, we modified the
GfaABC1D promoter, integrating three copies of the B
enhancer element to improve transgene expression in
astrocytes (GfaABC1D(B3), hereafter called G1B3)
(Fig. 1a) [22, 23, 26]. The transduction of mouse cortical
astrocytes with a LV encoding the GFP reporter gene under
the control of the GfaABC1D or G1B3 promoter demon-
strated that the B3 enhancer increased transgene expression
sixfold (Fig. 1b, c). This result is consistent with the find-
ings of de Leeuw et al., who showed that the integration of
the B3 enhancer in the Gfa2(B)3 promoter was 10 times
more active than the Gfa2 promoter alone [23].
We then used LV-G1B3-DsRednuc-miR124T to re-
evaluate the capacity of the VSV-G envelope for astrocyte
transduction. This LV was injected into the striatum of
GLT1-EGFP transgenic mice expressing the fluorescent
reporter gene in astrocytes (n= 3) (Fig. 1d–f). The animals
were killed 3 weeks later and immunohistochemical stain-
ing for DsRedNuc was performed. Most of the dsRednuc-
positive cells colocalized with the astrocytic GFP reporter
91.9 ± 1.3% (Fig. 1d–g). The 8% DsRed2Nuc+DAPI+
eGFP− cells are either GLT1-negative astrocytes, or neu-
rons with residual transgene expression as previously
demonstrated with other vectors [36]. Altogether, these
results demonstrate that the tropism of VSV-G-pseudotyped
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LV was dictated by the promoters driving transgene
expression rather than the VSV-G envelope.
We have shown that polymerase III promoters are
active in neurons [37]. We further characterized the
tropism of LVs pseudotyped with the VSV-G envelope,
by assessing the expression of a small hairpin RNA under
the control of the H1 promoter in astrocytes. The pCCL-
cPPT-H1-shGFP vector was injected into GLT1-EGFP
transgenic mice (n= 5). As positive control, the vector
was injected into Drd2-EGFP transgenic mice expressing
GFP in D2 dopamine receptor-positive (Drd2) GABAer-
gic neurons (n= 5). Efficient silencing of neuronal GFP
expression was observed in the Drd2-EGFP neurons, as
previously reported [28, 38] (Fig. 2a, b, d). GFP expres-
sion levels were strongly decreased in the astrocytes of
GLT1-EGFP mice, as compared with untransduced stria-
tum (Fig. 2f, g, i). These findings demonstrate that LV
pseudotyped with the VSV-G envelope efficiently trans-
duces astrocytes and can be used to overexpress or silence
genes of interest with polymerase II and polymerase III
promoters.
LV with retrograde transport properties
We used an improved version of the HiRet lentiviral vector,
to make use of retrograde transport and neuronal circuitry to
reach a large number of CNS regions affected in neurode-
generative disorders. This FuG/B2 envelope is a chimera of
the extracellular domain of rabies (Pasteur virus strain) and
the transmembrane and cytosolic domain of VSV-G, which
efficiently transduces neuronal and glial cells around the
injection site and leads to high rates of retrograde transport.
GFP fluorescence in the striatum greatly facilitates the
quantitative analysis of transduction. We therefore per-
formed a first side-by-side comparison of LV pseudotyped
with the VSV-G or FuG/B2 envelope. We injected pCCL-
cPPT-H1-shGFP-LV into GLT1-EGFP (n= 5) and Drd2-
EGFP mice (n= 5). The performances of LV-VSVG and
LV-FuG/B2 were equivalent in both the neurons and
astrocytes of the striatum (Fig. 2). For confirmation of these
data and analysis of not only the injection site, but also
transduced cells in projecting areas, we performed a second-
side-by-side comparison in C57BL/6 mice, with LV-VSVG
Fig. 1 Targeting astrocytes with the VSV-G envelope and an
astrocyte promoter. a Diagram of the astrocytic LV expressing
fluorescent reporter genes under the control of the GfaABC1D and
GfaABC1D(B)3 (G1B3 hereafter) promoters and the miR124T tar-
geting sequence. b Representative images of cortical astrocyte cultures
transduced with GfaABC1D-GFP-miR124T or G1B3-GFP-miR124T
LV pseudotyped with the VSV-G envelope (scale bar: 100 μm). Much
lower levels of GFP expression were observed with the GfaABC1D-
GFP-miR124T than with G1B3-GFP-miR124T. Immunostaining
demonstrated that transgene expression was restricted to GFAP-
positive astrocytes (red). c Transduction of mouse cortical astrocytes
using LV encoding a GFP reporter under the control of either a
GfaABC1D or a G1B3 promoter demonstrated that the B3 enhancer
increased transgene expression. Data are represented as means ± SD
and were analyzed with GraphPad Prism. Unpaired t test was per-
formed. d Images of GLT1-EGFP-positive astrocytes in the striatum of
adult mice. e Transduced striatal cells expressing DsRedNuc. fMerged
image of GLT-eGFP+ and DsRedNuc+ cells (scale bar: 50 μm). (g)
High-magnification image showing the colocalization of DsRednuc
and GFP (scale bar: 20 μm). h Analysis of astrocytic tropism with the
quantification of DsRedNuc- and GLT1-positive cells expressed as a
percentage ± SD.
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and LV-FuG/B2 expressing the GFP reporter gene (Fig. 3a,
b). GFP-positive cells were visible in the striatum when LV-
VSVG was used, confirming previous reports [39]. In the
ipsilateral cortex, only GFP-positive fibers were present
(Fig. 3b–d). For mice receiving injections of LV-FuG/B2,
we identified numerous transduced cells not only in the
striatum, but also in the ipsilateral and, to a lesser extent,
contralateral cortex (Fig. 3b–d). We investigated the retro-
grade transport properties of LV-FuG/B2 further, by ana-
lyzing regions of the brain projecting to the striatum.
Numerous GFP-positive cell bodies were detected in the
amygdala (Fig. 4a, b), substantia nigra pars compacta (SNc)
Fig. 3 Retrograde transport
with the GFP vector. a C57BL/
6 mice were injecting with either
VSV-G (n= 3) or FuG/B2 (n=
3) envelopes (b) expressing
green fluorescent reporter gene
under the control of the mouse
phosphoglycerate kinase 1
(PGK) promoter. c GFP-positive
cells are present in large areas of
the striatum after the injection of
VSV-G- and FuG/B2-
pseudotyped vectors (scale bar:
1 mm). d Consistent with
previous reports and the absence
of retrograde transport of LV-
VSVG, only GFP-positive fibers
were detected in the ipsilateral
cortex, whereas numerous GFP
cells were labeled with LV-FuG/
B2 in the ipsilateral cortex, but
also in the contralateral cortex
(scale bar: 100 µm).
Fig. 2 GFP silencing in striatal neurons and astrocytes with LV-
VSVG, or LV-FuG/B2. Drd2-EGFP (a) or GLT1-EGFP mice (f) (n=
5; scale bar: 100 μm) mice were injected with pCCL-cPPT-H1-shGFP
pseudotyped with the VSV-G (b–g) or FuG/B2 (c–h) envelope into the
striatum. The animals were killed 2 weeks later, striatal sections were
analyzed and GFP silencing was quantified (d, e, i, j). DAPI nuclear
counterstain was used on all striatal sections. Data are represented as
means ± SD and were analyzed with GraphPad Prism. For d and i, one-
way ANOVA was performed with Tukey post-hoc tests for multiple
comparisons. For e and j, unpaired t tests were performed. All data were
analyzed with GraphPad. NS non-significant, P > 0.05; *P ≤ 0.05; **P ≤
0.01; ***P ≤ 0.001. The values shown are means ± SD.
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Fig. 4 Retrograde transport of SIN-PGK-GFP-WPRE pseudotyped
with the FuG/B2 envelope. a Coronal sections showing the retrograde
transport of LV-FuG/B2 (scale bar: 1 mm). High-magnification images
of the (b) amygdala (c) substantia nigra pars compacta (SNc), (d)
thalamus and (e) cortex (scale bar: 100 µm).
























































Fig. 5 Analysis of retrograde transport in the motor (M1–M2) and
somatosensory (S1–S2) cortical areas. a Coronal sections showing the
retrograde transport of LV-FuG/B2 PGK-GFP reporter from the injection
site (see needle) along the entire anterior-posterior axis. b Motor and
somatosensory cortical cell bodies were quantified from +1.18 to
−0.70mm from the bregma within illustrated subareas described in the
Paxinos Atlas. c Total infected cell bodies in the motor and somato-
sensory areas of three mice. d Detailed quantification of infected cell
bodies within the motor and somatosensory areas of three mice. M1=
primary motor cortex, M2= secondary motor cortex, S1= primary
somatosensory cortex, S1BF= primary somatosensory cortex, barrel
field, S1DZ= primary somatosensory cortex, dysgranular region,
S1FL= primary somatosensory cortex, forelimb, S1HL= primary
somatosensory cortex, hindlimb, S1J-S1ULp= primary somatosensory
cortex, jaw region, and upper lip region, S1ULp = primary somato-
sensory cortex, upper lip region, S2= secondary somatosensory cortex.
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(Fig. 4a, c), thalamus (Fig. 4a, d), and cortex (Fig. 4a, e). In
the ipsilateral cortex, GFP-positive neurons were observed
up to 1.7 mm from the injection site (Fig. 5a). Some
variability was observed, probably reflecting the pattern of
diffusion of the vector in the striatum in each animal
(Fig. 5a, Figure S1). We assessed retrograde transport by
quantifying the number of transduced cells in the cortex
(17 sections; coordinates +2.68 mm and +0.02 mm from
the bregma). We detected 64,637–133,807 GFP-positive
neurons (Fig. 5c). The mouse brain atlas was then used as a
template to identify the different motor and somatosensory
cortical areas and define the somatotopy of retrograde
transport (Fig. 5b, Figure S1). The primary motor areas (M1
and M2) were well infected in all animals and the soma-
tosensory areas (S1–S2) were also infected, albeit to a lesser
extent (Fig. 5d). These data highlight the potential of the
FuG/B2 envelope for efficient gene transfer in large cortical
regions, but also the importance of optimizing striatal
injection coordinates to maximize retrograde transport.
GFP was expressed more strongly in the striatum than in
projecting areas (Fig. 6a), probably due to the presence of a
smaller number of vector copies in projecting areas than
at the site of injection in the striatum. We tested this
hypothesis by co-injecting SIN-PGK-mCherry-WPRE and
SIN-PGK-GFP-WPRE (1:1 ratio) pseudotyped with FuG/
B2 and analyzing the percentages of mCherry- and GFP-
positive cells in the striatum and cortex of C57/BL6 mice
(Fig. 6c). We have previously shown that the coinjection of
two lentiviruses results in a high proportion of striatal
neurons expressing both transgenes [40], and this was
confirmed here, with 72 ± 15% striatal cells expressing both
fluorescent reporter genes (Fig. 6d). In the cortex, this
proportion reached only 9 ± 1%, with the vast majority of
cortical cells expressing only the mCherry or GFP protein
(Fig. 6d). For further quantification of the levels of retro-
grade transport and transgene expression levels in the
striatum and cortex, we used the GFP reporter gene. The
amount of GFP mRNA has been shown to be proportional
to the amount of GFP protein [41, 42]. We used the
methods developed by Christodoulou et al. [29] to
demonstrate correlations between vector copy number
(VCN), GFP mRNA level and GFP fluorescence (Figure
S2). We infected HEK-293T cells with various amounts of
SIN-PGK-GFP-WPRE_VSV-G (5, 10, 25, 50, and 100 ng
p24; n= 2) and obtained a strong correlation (R2= 0.986)
between mean fluorescence intensity (protein), GFP mRNA
and VCN (DNA) (Figure S2A-D). We used this correlation
between MFI and VCN to estimate the striatal/cortical VCN
Fig. 6 Lower levels of transgene expression in the cortex than at
the injection site in the striatum due to the lower VCN in the
cortex than in the striatum. a Coronal sections showing the retro-
grade transport of LV-FuG/B2 encoding GFP (scale bar: 1 mm for the
hemisphere). High-magnification images of the striatum and cortex
(scale bar: 50 µm) (b) Quantification of mCherry- and GFP-positive
cells in the striatum and cortex of C57/BL6 mice. The data shown are
means ± SD. An unpaired t test was performed in GraphPad.
c Images of infected cells in the striatum (upper panels) and cortex
(lower panels). Cells are green (GFP+), red (mCherry+) or yellow
(coinfected) (scale bar: 20 µm). d Quantification of the cellular portion
of single-color and two-color cells indicating that the coinfection was
less frequent in the projecting areas than in the striatum.
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ratio in our experiment. We found that VCN was 16.7 times
higher in the striatum than in the cortex (Fig. 6a, b). If we
consider the mean VCN in the striatum to be 14 (Figure
S2E) (n= 3 mice), and assume that not all striatal cells are
transduced, then these data suggest a VCN of between 1 and
2 in the cortex, which is consistent with the co-infection
data (Fig. 6a). In the last experiment, we optimized the
striatal coordinates, based on the mouse cortico-striatal
connectome (n= 4, Figure 7= video) [21] and used a
purified vector to increase transduction efficiency. For fur-
ther analysis of the pattern of expression in these animals,
and of retrograde transport, in particular, we used an
advanced light-sheet microscope to image optically cleared
specimens according to the CLARITY protocol (n= 2). The
native GFP gave strong fluorescence and broad rostro-
caudal coverage of the striatum (video). Thus, under opti-
mal conditions, LV_FuG/B2 displays widespread diffusion
from the injection site, resulting in high levels of neuronal
and astrocytic transgene expression, and is associated with
the efficient transduction of projecting neurons.
Discussion
Clinical trials of gene therapy based on the intrapar-
enchymal administration of viral vectors have reported high
rates of neuronal cell transduction [43, 44]. However, the
important role of glial cells in neuronal functions and
plasticity is increasingly recognized, and advances in brain
mapping have revealed the role of neural networks and
connectivity in complex motor and cognitive functions [45].
We therefore hypothesize that targeting the glial cells and
neuronal circuits affected in neurodegenerative diseases
would maximize the therapeutic effect of gene therapy and
ensure long-term benefits. We developed a LV capable of
efficiently targeting both neurons and astrocytes, with ret-
rograde transport properties. This LV is particularly suitable
for the expression of large genes (beyond the cloning
capacity of AAV), the simultaneous expression of multiple
genes (for lysosomal storage disorders), complex expres-
sion systems (large cell-type specific promoters, regulated
or self-inactivating systems) and the targeting of dividing
CNS precursors.
We first addressed the issue of vector tropism by
developing a LV-VSVG, which efficiently transduces
astrocytes. We showed that the H1 polymerase III promoter,
often used to silence genes of interest, and the G1B3
polymerase II promoter, derived from GFAP, were highly
active in astrocytes in vitro and in vivo. The in vivo
experiments were conducted in the striatum of adult mice.
However, many studies have shown that astrocytes are
diverse in terms of both morphology and function [46]. This
finding was confirmed by the recent characterization of
subpopulations of molecularly different astrocytes [47].
Further studies of the G1B3 promoter will be required to
determine its expression profile in different brain regions,
astrocyte subclasses, and species. Finally, rapid advances in
genomics and massively parallel reporter assays should
expand the number of cell type-specific promoter/enhancer
sequences and provide new tools for studying glial func-
tions [48].
In gene transfer experiments, the expression profile of
the transgene is driven not only by the activity of the
promoter, but also by the interaction of viral envelope
glycoproteins with host cell surface receptors. In the
case of LV, the VSV-G envelope is a trimeric protein
(rhabdovirus family) that binds to its cellular receptor and
facilitates endocytosis of the virus. Finkelshtein et al.
demonstrated that the LDL receptor (LDLR) and other
LDLR family members, present in neurons and astrocytes
are the major receptors of VSV-G-pseudotyped LV [49].
Envelopes from alphaviruses and other members of the
rhabdovirus family have been used to alter the tropism of
LVs toward astrocytes. In particular, the glycoproteins
derived from the Mokola virus (MOK-G; rhabdovirus)
[24, 35], lymphocytic choriomeningitis virus (LCMV;
rhabdovirus) [50] and chikungunya virus [51] have been
used. However, the high titers of LV-VSVG, the efficient
transduction in the CNS of rodent and large-animal
models and accumulating preclinical and clinical data
have identified LV-VSVG as a candidate of choice for
overexpressing or silencing genes of interest in neurons
and astrocytes. We show here that LVs pseudotyped with
VSV-G efficiently target astrocytes in vitro and in vivo.
The second issue addressed in this study was the
development of a lentiviral vector able to reach extensive
areas of the brain. This is of particular importance given that
neurodegenerative disorders often begin in specific struc-
tures of the brain and then propagate to neuroanatomically
connected regions. Thus, therapeutic interventions targeting
most of the cells involved in these functional and anato-
mical networks might be more effective for preventing brain
damage. We optimized the distribution of the LV in dif-
ferent areas of the brain, by using a chimeric FuG/B2
envelope and optimizing stereotaxic coordinates based on
the corticostriatal connectome [21]. According to the pro-
jectome data, targeting the dorsolateral and intermediate
dorsal and ventrolateral regions of the striatum should favor
retrograde transport in cortical regions (primary and sec-
ondary motor and sensorimotor areas) of considerable
interest for the treatment of HD (Figure S1) [21, 52, 53] and
other neurodegenerative diseases affecting locomotion. We
found that neurons projecting from the cortex, amygdala,
thalamus, and substantia nigra were efficiently targeted by
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LV_FUG/B2. Mazarakis et al. reported that the retrograde
transport of equine infectious anemia virus pseudotyped
with the rabies envelope was not restricted to specific
neuronal cells [39]. Conversely, not all projection neurons
are equally susceptible to retrograde transport for AAV2-
retro [13].
The nicotinic acetylcholine receptor, the neuronal cell
adhesion molecule, and the low-affinity nerve growth factor
receptor (p75NTR) have been proposed as receptors med-
iating the entry of rabies virus. However, current data
suggest that they play a role in the infection process, but
probably not in viral entry [54]. Following entry via a
clathrin-based dynamin-2-dependant manner [55], the
endocytic vesicles containing rabies-G-pseudotyped LV
fuse to an early Rab5-positive endosome. Interestingly, for
rabies virus, particles that are still enveloped are transported
in primary neuronal cultures [56]. However, the precise
mechanism involved is still poorly understood. Retrograde
transport involves binding to the cytoplasmic dynein
motors, which transport cargoes toward the minus end of
the microtubules [57]. The sequential activities of Rab5 and
Rab7 are required for the coupling of clathrin-dependent
endocytosis to fast retrograde axonal transport [58]. Indeed,
the conversion of Rab5-positive vesicles into Rab7-positive
vesicles may control the generation of axonal retrograde
carriers. Rab5 is thought to be responsible for localized
axonal movements, whereas Rab7 is responsible for long-
range axonal transport [58]. The long-distance axonal
transport of AAV9 is also driven by dynein and kinesin-2,
and trafficking in a highly motile Rab7-positive compart-
ment [59].
The combined use of the retrograde transport properties
of LVs and an optimized surgical and delivery procedure
based on projectome/connectome data greatly improve
transgene distribution in the CNS and make it possible to
target both neurons and astrocytes efficiently. This gene
delivery system constitutes a powerful tool for studies of
brain connectivity and assessments of the functional con-
tribution of afferents in a circuit. It also opens up new
possibilities for the local delivery of LVs to highly inter-
connected regions of the brain, to achieve a broad dis-
tribution and slow the progression of neurodegenerative
disorders.
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